REBIOSTENT
Reinforced Bioresorbable Biomaterials for Therapeutic Drug Eluting Stents
| Coordinatore | LUCIDEON LIMITED
Organization address
address: QUEENS ROAD PENKHULL contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 5˙874˙420 € |
| EC contributo | 4˙579˙131 € |
| Programma | FP7-NMP
Specific Programme "Cooperation": Nanosciences, Nanotechnologies, Materials and new Production Technologies |
| Code Call | FP7-NMP-2013-SME-7 |
| Funding Scheme | CP-TP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2016-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
LUCIDEON LIMITED
Organization address
address: QUEENS ROAD PENKHULL contact info |
UK (STOKE ON TRENT) | coordinator | 644˙500.00 |
| 2 |
THE UNIVERSITY OF WESTMINSTER
Organization address
address: REGENT STREET 309 contact info |
UK (LONDON) | participant | 548˙473.00 |
| 3 |
FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
Organization address
address: Hansastrasse 27C contact info |
DE (MUENCHEN) | participant | 470˙035.00 |
| 4 |
ARTERIUS LIMITED
Organization address
address: BRADFORD BIO INCUBATOR BRADFORD contact info |
UK (BRADFORD) | participant | 366˙132.00 |
| 5 |
UNIVERSITY OF SOUTHAMPTON
Organization address
address: Highfield contact info |
UK (SOUTHAMPTON) | participant | 353˙863.00 |
| 6 |
RUHR-UNIVERSITAET BOCHUM
Organization address
address: Universitaetstrasse 150 contact info |
DE (BOCHUM) | participant | 325˙584.00 |
| 7 |
Vornia Limited
Organization address
address: "UPPER NEWCASTLE ROAD, BUSINESS INNOVATION CENTRE, NATIONAL UNIVERSITY OF IRELAND GALWAY" contact info |
IE (GALWAY) | participant | 312˙990.00 |
| 8 |
LIFE AND DEVICE SRL
Organization address
address: VIA GIOACCHINO QUARELLO 11 A contact info |
IT (TORINO) | participant | 296˙025.00 |
| 9 |
FUNDACION TEKNIKER
Organization address
address: CALLE INAKI GOENAGA 5 contact info |
ES (EIBAR GUIPUZCOA) | participant | 238˙162.00 |
| 10 |
POLITECNICO DI TORINO
Organization address
address: Corso Duca degli Abruzzi 24 contact info |
IT (TORINO) | participant | 236˙946.00 |
| 11 |
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Organization address
address: The Old Schools, Trinity Lane contact info |
UK (CAMBRIDGE) | participant | 208˙315.00 |
| 12 |
EURESCOM-EUROPEAN INSTITUTE FOR RESEARCH AND STRATEGIC STUDIES IN TELECOMMUNICATIONS GMBH
Organization address
address: Wieblinger Weg 19/4 contact info |
DE (HEIDELBERG) | participant | 204˙807.00 |
| 13 |
FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN NURNBERG
Organization address
address: SCHLOSSPLATZ 4 contact info |
DE (ERLANGEN) | participant | 199˙899.00 |
| 14 |
SPINTEC ENGINEERING GMBH
Organization address
address: KURBRUNNENSTRASSE 22 contact info |
DE (AACHEN) | participant | 173˙400.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Active therapeutic biodegradable and biocompatible materials are highly in demand. These are required for the production of medicinal products in a variety of areas including implant technology, tissue engineering, drug delivery and wound healing. Within implant technology such biomaterials can be used for dental, bone and cardiovascular implants. Tailored mechanical properties, biocompatibility and degradation rate is the key to the development for a specific implant.
Stents are tubular type implants that are deployed most commonly to recover the shape of narrowed arterial segments. Although, the clinical use of stents is widespread, they cause adverse responses including inflammation, in-stent restenosis and thrombosis. Endothelialisation of the stent greatly reduces these adverse reactions. In contrast to permanent stents there is great attraction in the notion of a biodegradable stent that recovers and maintains arterial shape and then gradually disappears and avoids further complications.
In this multi-institution & disciplinary SME focussed project we will aim to provide the technological framework that leads to the production of reinforced polymeric biomaterials tailored towards stent manufacturing without adverse effects. Both natural and synthetic polymers will be produced and used. These will be reinforced and functionalised using a variety of techniques. Controlled delivery of suitable positive additives including antimitotic factors will be aimed for and their release monitored. These highly functionalised active biomaterials will be characterised thoroughly for material properties, biocompatibility, rate of biodegradation and used for the production of ideal stents. These will be characterized thoroughly leading to preclinical validation. All required production and manufacturing guidelines will be followed.'